Metrics as of 10/17/2026, 05:10 AM (Berlin time), refresh in progress.
Puma Biotechnology Stock
Puma Biotechnology, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Alan H. Auerbach
- Employees
- 179
- Market cap
- $507 M
- IPO
- 24/04/2012
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage…
Puma Biotechnology stock: price history
1D
-6.6%
1W
-4.5%
1M
+4.7%
6M
+31.6%
YTD
+65.2%
1Y
+81.7%
2Y
+241.3%
5Y
+62.5%
10Y
-81.9%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~51% stronger price swings than usual
Puma Biotechnology stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
1 more assignment (Enabler/Second row) Pro-only.
Puma Biotechnology focuses on the development and global commercialization of cancer therapies. The core product is the orally administered active ingredient Neratinib (PB272), which is primarily used to treat HER2-positive breast cancer in various stages. The company's main source of revenue is product sales, while a smaller portion of revenues derives from royalties. The company maintains various strategic partnerships and sub-licensing agreements worldwide to expand its therapeutic options and promote market penetration.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Puma Biotechnology
Analyst assessment of Puma Biotechnology
0
STRONG BUY
8
BUY
8
HOLD
4
SELL
0
STRONG SELL
20
TOTAL · Buy
As of: 07/08/2026
Puma Biotechnology stock metrics
P/E
18.33
P/B
3.61
EV/EBITDA
10.53
RETURN ON EQUITY
5.9%
NET MARGIN
14.5%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.6%
FLOAT SHARES
40,082,646
AVG. DAILY VOLUME (30D)
324,748
Insider transactions (SEC)
WILSON TROY EDWARD
Cesano Alessandra
Cesano Alessandra
NOUGUES MAXIMO F
HUNT DOUGLAS M
Attention
Price since yesterday: -6.6%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about Puma Biotechnology stock
What does Puma Biotechnology do?
Puma Biotechnology, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Alan H. Auerbach, the company employs around 179 people.
The IPO was on 24/04/2012; the stock trades on NASDAQ under the ticker PBYI.
What do analysts say about Puma Biotechnology stock?
20 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
This is an external assessment, not a statement by Market Jury.
When does Puma Biotechnology report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 51% stronger than usual.
Does Puma Biotechnology pay a dividend?
No, Puma Biotechnology currently does not pay a dividend.
Which stocks are comparable to Puma Biotechnology?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Puma Biotechnology stock analyzed?
Clicking "Analyze stock" lets five strategies assess Puma Biotechnology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.